Alteration in Dissolution Characteristics of Gelatin-Containing Formulations: A Review of the Problem, Test Methods, and Solutions

Publication
Article
Pharmaceutical TechnologyPharmaceutical Technology-04-02-2002
Volume 26
Issue 4

Eventual change in the dissolution characteristics of some dosage forms, which is ascribed to cross-linking of gelatin, continues to present challenges to drug manufacturers. The authors discuss the causes, mechanisms, and solutions to the problem.

External Link - article-14096.pdf

Articles in this issue
Effect of Extragranular Microcrystalline Cellulose on Compaction, Surface Roughness, and In Vitro Dissolution of a Self-Nanoemulsified Solid Dosage Form of Ubiquinone
The Usefulness of 0.45 &#181m&#150Rated Filter Membranes
Outsourcing Outlook
Monitoring Blend Uniformity with Effusivity
Using Ion Mobility Spectrometry for Cleaning Verification in Pharmaceutical Manufacturing
Bush Budget Combats Bioterrorism, Promotes Drug Safety
Alteration in Dissolution Characteristics of Gelatin-Containing Formulations: A Review of the Problem, Test Methods, and Solutions
E-Procurement — Successfully Using and Managing Reverse Auctions
Liposomes: A Review
Recent Videos
Lee Cronin, founder and CEO of Chemify
Related Content
Future and media concept | Image Credit: ©peshkova - stock.adobe.com

Integrating Advanced Technologies for Pharma Analysis

Cynthia A. Challener
December 8th 2024
Article

Automation technologies provide real potential to improve responsiveness and decision-making in drug development.

Drug Solutions Podcast: Applying Appropriate Analytics to Drug Development

Drug Solutions Podcast: Applying Appropriate Analytics to Drug Development

March 26th 2024
Podcast

In this episode of the Drug Solutions Podcast, Jan Bekker, Vice President of Business Development, Commercial and Technical Operations at BioCina, discusses the latest analytical tools and their applications in the drug development market.

Communication between the manufacturing plant and retail stores. | Image Credit: © Cagkan - © Cagkan - stock.adobe.com

Abzena Expands Analytical Services with GMP Cell-Based Potency Testing in US and UK

Feliza Mirasol
November 22nd 2024
Article

The company has expanded its early and late phase analytical capabilities by including GMP cell-based potency assays at its sites in Cambridge, UK, and San Diego, Calif.

Communication between the manufacturing plant and retail stores. | Image Credit: © Cagkan - © Cagkan - stock.adobe.com

Three New European Facilities Established by BioPharmaSpec for R&D

Feliza Mirasol
November 21st 2024
Article

Located in German, Italy, and Lithuania, the new European facilities will specialize in drug discovery and R&D services.

Communication between the manufacturing plant and retail stores. | Image Credit: © Cagkan - © Cagkan - stock.adobe.com

Newly Opened Innovation Center in New Jersey Gives Avantor Advantage in Solving Life Sciences Challenges

Feliza Mirasol
November 15th 2024
Article

Avantor's newly launched expanded Innovation Center in Bridgewater, NJ, is designed for integrated workflows and features purpose-built collaboration spaces.

Two scientists wearing lab coats and safety glasses analyzing data displayed on a computer screen in a laboratory setting | Image Credit: © NCST Studio - © NCST Studio - stock.adobe.com

Untethered Data: Unifying and Contextualizing Drug Discovery Data

Chris Stumpf
November 5th 2024
Article

Capturing and curating R&D data are crucial to realizing the full value of advanced analytics.